|
Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer.
Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer. Read the article on Healio.com
DetailsAt ARVO 2018, Gerhard Garhöfer, MD, discusses our clinical NT-004 study investigating the effect of NovaTears(R) on tear film thickness in dry eye patients:
Heidelberg, Germany – April 24, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May…
DetailsDuring OIS@ASCRS2018 in Washington, D.C., Bernhard Günther gave an interview with Healio/OSN about Novaliq Inc.’s clinical and business progress to date. Mr. Günther shared his views on how Novaliq plans to leverage the benefits of the company‘s water-free EyeSol® drug delivery technology to serve the growing U.S. eye care market.
